Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

2021 The Lancet Oncology 984 citations

Keywords

MedicineSorafenibBevacizumabHepatocellular carcinomaInternal medicineClinical endpointBiosimilarOncologyGastroenterologyPhases of clinical researchResponse Evaluation Criteria in Solid TumorsAdverse effectClinical trialChemotherapy

Affiliated Institutions

Related Publications

Publication Info

Year
2021
Type
article
Volume
22
Issue
7
Pages
977-990
Citations
984
Access
Closed

External Links

Citation Metrics

984
OpenAlex

Cite This

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. (2021). Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. The Lancet Oncology , 22 (7) , 977-990. https://doi.org/10.1016/s1470-2045(21)00252-7

Identifiers

DOI
10.1016/s1470-2045(21)00252-7